# META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

> **NCT07689604** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 18 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia (AIHA)

## Interventions

- **BIOLOGICAL:** Metabolically Armed Autologous CD19 CAR T-Cell therapy

## Key facts

- **NCT ID:** NCT07689604
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-20
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689604, "META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*